{"entity":{"id":"nct04221035","kind":"trial","name":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","aka":[],"tldr":"A phase 3 trial of Vincristine, Carboplatin, Etoposide, Vindesine, Dacarbazine, Ifosfamide, Doxorubicin, Busulfan, Melphalan, Thiotepa, Dinutuximab, Cisplatin and Irinotecan in High-risk neuroblastoma, run by Gustave Roussy, Cancer Campus, Grand Paris, now recruiting.","summary":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) is a phase 3 interventional study registered as NCT04221035 by Gustave Roussy, Cancer Campus, Grand Paris, with 800 participants planned, started 2019-11-05 and due to reach its primary completion in 2026-11. Interventions recorded: Vincristine, Carboplatin, Etoposide, Vindesine, Dacarbazine, Ifosfamide, Doxorubicin, Busulfan, Melphalan, Thiotepa, Radiotherapy, Dinutuximab Beta, Cisplatin, Temozolomide 100 MG, Irinotecan, Cyclophosphamid. Conditions recorded: High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy.\n\nLinked to the drug Vindesine because the registry names it among its interventions and High-risk neuroblastoma among its conditions. Registry record only: no result has been read by an editor.","status":"recruiting","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT04221035","url":"https://clinicaltrials.gov/study/NCT04221035"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["neuroblastoma-high-risk"],"sections":[],"technologies":[],"targets":[],"drugs":["vincristine","carboplatin","etoposide","vindesine","dacarbazine","ifosfamide","doxorubicin","busulfan","melphalan","thiotepa","dinutuximab","cisplatin","irinotecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04221035","phase":"3","setting":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","enrolled":800,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04221035/","neighbours":{"cancer":[{"id":"neuroblastoma-high-risk","kind":"cancer","name":"High-risk neuroblastoma","route":"/cancers/neuroblastoma-high-risk/"}],"drug":[{"id":"busulfan","kind":"drug","name":"Busulfan","route":"/drugs/busulfan/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"dacarbazine","kind":"drug","name":"Dacarbazine","route":"/drugs/dacarbazine/"},{"id":"dinutuximab","kind":"drug","name":"Dinutuximab (ch14.18) / dinutuximab beta","route":"/drugs/dinutuximab/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/"},{"id":"ifosfamide","kind":"drug","name":"Ifosfamide","route":"/drugs/ifosfamide/"},{"id":"irinotecan","kind":"drug","name":"Irinotecan (and liposomal irinotecan)","route":"/drugs/irinotecan/"},{"id":"melphalan","kind":"drug","name":"Melphalan (including hepatic delivery system)","route":"/drugs/melphalan/"},{"id":"thiotepa","kind":"drug","name":"Thiotepa","route":"/drugs/thiotepa/"},{"id":"vincristine","kind":"drug","name":"Vincristine","route":"/drugs/vincristine/"},{"id":"vindesine","kind":"drug","name":"Vindesine","route":"/drugs/vindesine/"}]}}